TIME Companies

AstraZeneca Rejects Pfizer’s ‘Final’ $116 Billion Bid

Viagra drugs made by Pfizer and Nexiam (Generic name - Esomeprazole) made by the pharmaceutical firm AstraZeneca in a Pharmacy on May 15, 2014 in Johannesburg.
Christopher Furlong—Getty Images Viagra drugs made by Pfizer and Nexiam (Generic name - Esomeprazole) made by the pharmaceutical firm AstraZeneca in a Pharmacy on May 15, 2014 in Johannesburg.

AstraZeneca declined the bid that would have made it worth $116 billion because the offer 'undervalues the company and its attractive prospects'

AstraZeneca has rejected Pfizer’s improved “final” bid of $92 per share, which would have made the British pharmaceutical giant worth about $116 billion, saying that the new offer “undervalues the company and its attractive prospects.”

The pursuit by American firm Pfizer’s, based on a strategy to cut its tax expenses, has been scrutinized out of fears that it would impede AstraZeneca’s drug research and cut jobs.

The debate over a potential takeover has embroiled both politicians and trade unions in the U.K., where AstraZeneca currently employes 6,700 people. AstraZeneca’s shares fell over 13% in early trading after the rejection of the offer.

[BBC]

Tap to read full story

Your browser is out of date. Please update your browser at http://update.microsoft.com


YOU BROKE TIME.COM!

Dear TIME Reader,

As a regular visitor to TIME.com, we are sure you enjoy all the great journalism created by our editors and reporters. Great journalism has great value, and it costs money to make it. One of the main ways we cover our costs is through advertising.

The use of software that blocks ads limits our ability to provide you with the journalism you enjoy. Consider turning your Ad Blocker off so that we can continue to provide the world class journalism you have become accustomed to.

The TIME Team